Core Viewpoint - Huaxi Biological is experiencing a painful growth period, with significant declines in both revenue and profit in the first half of 2025, primarily due to the structural collapse of its core business, particularly the skin science innovation transformation segment [1][3][4]. Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% [1][3]. - The company's net profit after excluding non-recurring gains and losses fell by 45%, amounting to 174 million yuan [3][5]. - For Q2 2025, revenue was 1.183 billion yuan, a decline of 18.44%, while net profit increased by 20.89% to 119 million yuan, marking the first recovery in net profit margin since Q1 2024 [3][5]. Core Business Challenges - The skin science innovation transformation business, which previously accounted for nearly half of the revenue, continued to decline, with a 33.97% drop in revenue to 912 million yuan in the first half of 2025 [1][3][5]. - This segment's revenue had already decreased by 31.62% in 2024, indicating a persistent downward trend [3][5]. Business Strategy and Reforms - Since 2024, Huaxi Biological has initiated a series of reforms aimed at improving management efficiency and reviving business performance, including restructuring business processes and enhancing organizational capabilities [7][8]. - The chairman and general manager, Zhao Yan, has taken a hands-on approach to manage core business segments, but the effects of these reforms have yet to be reflected in the financial results [7][8]. R&D and Future Directions - In the first half of 2025, Huaxi Biological invested 231 million yuan in R&D, a 15.25% increase, focusing on high-barrier raw materials and medical terminal businesses [8]. - The company is undergoing a strategic upgrade, shifting its R&D focus towards glycoscience and cell biology, while maintaining that the decline in functional skincare products is not due to missing market opportunities [8][9].

21世纪经济报道记者雷晨 皮肤科学业务33.97%的营收降幅，折射出从规模扩张到效益优先的战略转向；而原料业务海外市场两 位数增长、医疗终端产品创新突破，则揭示其底层技术护城河的韧性。 从半年报来看，华熙生物多项核心财务指标同比下滑。 2025年上半年，中国功能性护肤品行业经历深度调整，头部企业华熙生物（688363.SH）在战略转型的 阵痛中交出阶段性答卷。 半年报显示，公司营收与净利润同比双降，但二季度经营质量已现曙光——净利润率逆势回升，存货周 转效率提升，释放出内部变革的信号。 这场由公司董事长、总经理赵燕亲自挂帅的深度调整，能否将短期业绩压力转化为长期价值重构的契 机？ 业绩短期承压，二季度有所改善 当化妆品行业从流量红利迈入存量博弈，华熙生物撕下"增长神话"的标签。 公司短期业绩承压，主要源于皮肤科学创新转化业务的大幅下滑。 根据财报披露，皮肤科学创新转化业务（以功能性护肤品为主）上半年实现收入9.12亿元，同比下降 33.97%，占主营业务收入比例从上年同期的52.1%降至40.36%。 该业务的下滑，一方面受化妆品行业整体竞争加剧、流量成本攀升影响，另一方面也与公司主动调整营 销策略，从"规模 ...

Core Viewpoint - Huaxi Biological reported significant marginal improvement in performance for the first half of 2025, with a notable recovery in the second quarter despite an overall decline in revenue and profit for the first half [1][2]. Financial Performance - For the first half of 2025, Huaxi Biological achieved revenue of 2.26 billion yuan, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million yuan, down 35.38% [2][3]. - The second quarter saw a revenue of 1.18 billion yuan, a decline of 18.44% year-on-year, but net profit increased by 20.89% to 119 million yuan, marking a return to growth after a year [5]. - Operating cash flow turned positive in the second quarter with a net inflow of 241 million yuan, reversing the outflow from the first quarter [5]. Business Segments - The raw materials segment showed resilience with revenue of 626 million yuan, a slight decline of 0.58%, accounting for 27.70% of total revenue [6]. - The medical terminal business generated 673 million yuan, down 9.44%, with skin-related products contributing 467 million yuan, a decrease of 1.8% [6]. - The skin science innovation transformation business reported revenue of 912 million yuan, down 33.97%, representing 40.36% of total revenue [7]. - The nutrition science innovation transformation business achieved revenue of 38 million yuan, a year-on-year increase of 32.40% [8]. Research and Development - R&D investment totaled 231 million yuan, up 15.25%, with R&D expenses accounting for 10.22% of revenue, an increase of 3.09 percentage points [8]. Management Changes - The company is undergoing transformation with the return of the CEO to frontline operations, focusing on restructuring management and business direction [9][10]. - Significant adjustments include a shift from sales volume to efficiency-oriented marketing strategies, resulting in a 12.46 percentage point decrease in sales expense ratio in the second quarter [10][11].

上 市 公 司 美容护理 ——Q2 业绩拐点已现，科技实力构建业务护城河 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2025 年 08 月 26 日 | | --- | --- | | 收盘价（元） | 58.18 | | 一年内最高/最低（元） | 84.59/42.51 | | 市净率 | 4.0 | | 股息率%（分红/股价） | 0.19 | | 流通 A 股市值（百万元） | 28,024 | | 上证指数/深证成指 | 3,868.38/12,473.17 | | 注："股息率"以最近一年已公布分红计算 | | 2025 年 08 月 27 日 华熙生物 (688363) | 基础数据: | 2025 年 06 月 30 日 | | --- | --- | | 每股净资产（元） | 14.60 | | 资产负债率% | 17.59 | | 总股本/流通 A 股（百万） | 482/482 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 08-26 09-26 10-26 11-26 12-26 01-26 02-26 03-26 04-26 ...

Core Insights - Huaxi Biological Technology Co., Ltd. reported a 20.89% year-on-year increase in net profit attributable to shareholders in Q2 2025, marking the first time since Q1 2024 that both year-on-year and quarter-on-quarter profit margins have improved, indicating initial success of strategic transformation [1] - The company generated a net cash flow of 220 million yuan from operating activities in the first half of the year, with a profit cash ratio of 98.6%, reflecting improved accounts receivable turnover and high-quality business returns [1] - Inventory turnover days decreased from 391 days in Q1 to 321 days in Q2, with inventory value reduced by 75.72 million yuan, demonstrating effective inventory management strategies [1][2] Business Strategy - Huaxi Biological focuses on an integrated business model from raw materials to end products, particularly in the field of aging intervention, providing comprehensive solutions across pharmaceuticals, medical aesthetics, nutritional science, and dermatology [2] - Following a systematic reform initiated by General Manager Zhao Yan in March, the company has restructured its brand communication and organizational framework, shifting from a sales-centric model to a precise marketing loop, resulting in a 12.46 percentage point decrease in sales expense ratio in Q2 [2] - The company has seen significant results from brand adjustments, with the brands "Runbaiyan" and "Kuadi" undergoing changes by the end of Q2, alongside a provision for asset impairment of 48.37 million yuan [2] Revenue Performance - In the first half of 2025, Huaxi Biological achieved 626 million yuan in revenue from its raw materials segment, with international market sales accounting for 52.93%, and double-digit growth in Europe, Southeast Asia, and Japan [3] - The sales volume of the "First" brand HA increased by 23% to 80 tons, generating revenue of 56.58 million yuan, a 61.28% year-on-year increase, while the main brand HA sales volume grew by 9% to 150 tons [3] Research and Development - The company invested 231 million yuan in R&D in the first half of 2025, a 15.25% increase year-on-year, focusing on high-end hyaluronic acid and new bioactive products [4] - Huaxi Biological streamlined 30% of its R&D projects, concentrating on three key areas: extracellular matrix, intercellular communication, and intracellular processes, resulting in 340 new authorized patents, including 29 invention patents [4] - The successful application of "INFIHA Cell Repair Technology" and "CT50 Cell Energy Liquid" has led to over 50% of revenue from barrier repair and anti-aging products [4] Market Positioning - Industry experts believe that Huaxi Biological's strategic adjustments have entered a critical phase, with the profit recovery in Q2 validating the effectiveness of the transformation path [5] - The continuous conversion of R&D results and the enhancement of the high-end product matrix are expected to help the company rebuild competitive barriers in the biomaterials sector [5]

Core Viewpoint - Huaxi Biological is experiencing a significant decline in performance, with both revenue and profit decreasing sharply in the first half of 2025, primarily due to the structural collapse of its core business in skin science innovation [1][3][4]. Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.26 billion yuan, a year-on-year decrease of 19.57% [2][3]. - The net profit attributable to shareholders was 221 million yuan, down 35.38% compared to the same period last year [2][3]. - The net profit after deducting non-recurring gains and losses fell by 45%, amounting to 174 million yuan [2][3]. - The cash flow from operating activities decreased by 17.49%, totaling 218 million yuan [2]. - As of the end of the reporting period, the net assets attributable to shareholders were 7.03 billion yuan, reflecting a 3.27% increase from the previous year [2]. Business Segment Performance - The skin science innovation transformation business, which previously accounted for nearly half of the revenue, continued its decline, with a 33.97% drop in revenue to 912 million yuan, representing 40.36% of the company's main business income [3][4]. - The raw material business saw a slight decline of 0.58%, generating 626 million yuan, while the medical terminal business reported a 9.44% decrease, with revenue of 673 million yuan [5]. Strategic Reforms - Since 2024, Huaxi Biological has initiated a series of reforms aimed at improving management efficiency and business recovery, including restructuring business processes and enhancing organizational talent [6]. - The chairman has taken a hands-on approach to manage core business segments, but the effects of these reforms have yet to be reflected in the financial results [6][7]. - The company is currently undergoing its third strategic upgrade, focusing on research in glycoscience and cell biology [7]. Market Context - The decline in Huaxi Biological's performance contrasts sharply with competitors like Jinbo Biological, which reported a 42.43% increase in revenue in the same period, highlighting the competitive pressures in the functional skincare market [8].

功能性护肤品行业主要上市公司：贝泰妮(300957.SZ);华熙生物(688363.SH);上海家化(600315.SH);创尔 生物(831187.NQ);巨子生物(02367.HK);敷尔佳(301371.SZ) 本文核心数据：中国功能性护肤品行业上市企业线上渠道营业收入及其占比 转自：前瞻产业研究院 线上渠道为主流，专业渠道贡献有限 | | 渠道 | 优势 | 劣势 增长驱动 | | --- | --- | --- | --- | | 线上渠道 | | 天猫、抖音、快手、京东、1）触达范围广易出爆品: | 线上基本触达可触达群 体,但仍是消费者回购的 流量成本升高 | | | 拼多多等私域流量 | 2) 渠道成本较线下低,利润率高 | 主要场所及新品牌营销 | | | | | 的主战场 | | 线下渠道 | 直营专柜、KA 渠道、CS | 1)终端价格可控、利润率可控: | 1) 渠道成本高,较线上 2) 专业渠道门槛较高,开拓线下自营、中高端渠 | | | | | 高出约 55个百分点: 1) 新锐集团利用品牌力 | | | 渠道、专业渠道(OTC& | | OTC 渠道仅械享号可以通(如屈臣氏): ...

Core Viewpoint - Huaxi Biological's performance continues to decline, with significant drops in revenue and net profit in the first half of 2025, indicating ongoing pressure on the company's operations [2][5]. Financial Performance - The company's revenue for the first half of 2025 was 2.261 billion yuan, a year-on-year decrease of 19.57% [2][4]. - The net profit attributable to shareholders was 220 million yuan, down 35.38% year-on-year [2]. - The skin science innovation transformation business, which accounts for 40.36% of total revenue, saw a revenue decline of 33.97% to 912 million yuan [5][6]. Business Segments - The skin science innovation transformation business is the most severely affected segment, with a significant drop in revenue [5]. - The raw material business generated 626 million yuan, with a slight decline of 0.58%, while the medical terminal business brought in 673 million yuan, down 9.44% [6]. - The medical products in the terminal business achieved 467 million yuan in revenue, a decrease of 1.8% [6]. Reform Measures - The company has implemented significant reforms, including the return of the general manager to frontline operations to drive change [7]. - Sales expenses decreased by 31.44% year-on-year, attributed to reduced promotional costs in the skin science innovation transformation business [7]. - Research and development investment increased to 10.22% of total revenue, up from 7.13% in the previous year, indicating a strong commitment to innovation despite poor performance [7]. Quarterly Insights - In the second quarter of 2025, the company reported revenue of 1.183 billion yuan, a decline of 18.44% year-on-year, but net profit increased by 20.89% to 119 million yuan [8]. - The net profit margin rose for the first time since the first quarter of 2024, suggesting that reform measures may be starting to yield positive results [8].

Market Overview - The Shanghai Composite Index fell by 1.76% on August 27, with only one industry, telecommunications, showing an increase of 1.66% [1] - The beauty and personal care sector experienced the largest decline, dropping by 3.86%, followed by the real estate sector, which fell by 3.51% [1] Capital Flow - The net outflow of capital from the two markets reached 129.75 billion yuan, with all sectors under Shenwan showing a net outflow [1] - The computer industry had the highest net outflow at 16.31 billion yuan, followed by the pharmaceutical and biological sector with a net outflow of 12.32 billion yuan [1] Beauty and Personal Care Sector - The beauty and personal care sector saw a net outflow of 755 million yuan, with 29 stocks in the sector; only 2 stocks rose while 26 fell [1] - The stocks with the highest net inflow included: - Wanjian Medical: 10.31 million yuan - Jiaheng Jiahua: 6.45 million yuan - Marubi Biological: 3.16 million yuan [1] - The stocks with the highest net outflow included: - Proya: 247 million yuan - Aimeike: 121.78 million yuan - Qingdao Kingking: 84.85 million yuan [1] Individual Stock Performance - Proya (603605) decreased by 7.59% with a turnover rate of 6.81% and a net outflow of 247.03 million yuan [2] - Aimeike (300896) fell by 3.88% with a turnover rate of 2.98% and a net outflow of 121.78 million yuan [2] - Qingdao Kingking (002094) dropped by 3.31% with a turnover rate of 10.87% and a net outflow of 84.85 million yuan [2] - Other notable declines included Huaxi Biological (688363) down by 2.25% and Zhongshun Jierou (002511) down by 4.26% [2]

Market Overview - The medical beauty sector experienced a decline of 3.11% on August 27, with Aimeike leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Aimeike (300896) closed at 190.03, down 3.88%, with a trading volume of 62,200 shares and a transaction value of 1.207 billion yuan [1] - Huaxi Biological (688363) closed at 56.87, down 2.25%, with a trading volume of 99,400 shares and a transaction value of 580 million yuan [1] - Jinbo Biological (832982) closed at 304.80, down 3.24%, with a trading volume of 10,300 shares and a transaction value of 319 million yuan [1] - ST Meigu (000615) remained unchanged at 3.33, with a trading volume of 142,300 shares and a transaction value of 47.7013 million yuan [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 199 million yuan from main funds, while retail investors contributed a net inflow of 153 million yuan [1] - Aimeike experienced a net outflow of 143 million yuan from main funds, with retail investors contributing a net inflow of 98.8281 million yuan [2] - Huaxi Biological had a net outflow of 57.973 million yuan from main funds, but a net inflow of 53.4443 million yuan from retail investors [2]